Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (NVO)
NYSE:NVO
NVO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$59.32 - $148.15
Previous CloseN/A
Volume3.65M
Average Volume (3M)7.97M
Market Cap
$284.58B
Enterprise Value$393.88B
Total Cash (Recent Filing)kr9.53B
Total Debt (Recent Filing)kr2.00B
Price to Earnings (P/E)19.7
Beta0.84
Next Earnings
May 07, 2025EPS Estimate
0.83Last Dividend Ex-Date
Mar 31, 2025Dividend Yield1.83%
Share Statistics
EPS (TTM)0.89
Shares Outstanding3,390,128,000
10 Day Avg. Volume9,732,171
30 Day Avg. Volume7,973,406
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.10
Price to Cash Flow (P/CF)61.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$84.83Price Target Upside34.91% Upside
Rating ConsensusHold
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsSTRIDE data clearly showed statistical benefit of Ozempic in pain-free walking distance and maximum walking distance.
Strategic LicensingNovo licenses United Laboratories' triple agonist UBT251, tapping into the Chinese biotech market and showcasing the company's strategic moves in the obesity sector.
Bears Say
Market CompetitionEli Lilly's Zepbound has now overtaken Novo's Wegovy both in terms of US weekly total prescriptions and US weekly prescriptions for the starting doses.
Sales GuidanceAnalysts expect Novo Nordisk to lower its sales guidance, narrowing the range, which is inconsistent with the higher uncertainty.
---
Ownership Overview
―
Insiders
1.33% Mutual Funds
0.12% Other Institutional Investors
98.46% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NVO FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was $59.32 and its highest was $148.15 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $284.58B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is May 07, 2025 which is in 20 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Feb 05, 2025. The company reported $0.886 earnings per share for the quarter, beating the consensus estimate of $0.831 by $0.055.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.
Does Novo Nordisk pay dividends?
Novo Nordisk pays a Semiannually dividend of $0.787 which represents an annual dividend yield of 1.83%. See more information on Novo Nordisk dividends here
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.83.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of $0.886 in its last earnings report, beating expectations of $0.831. Following the earnings report the stock price went up 3.771%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in NVO
---
Novo Nordisk Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$84.83 (34.91% Upside)
$84.83 (34.91% Upside)
Blogger Sentiment
Bullish
NVO Sentiment 80%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 912.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.64%
12-Months-Change
Fundamentals
Return on Equity
82.03%
Trailing 12-Months
Asset Growth
38.79%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
---
NVO Company Deck
---
NVO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong year for Novo Nordisk with substantial sales and profit growth, expansion in patient reach, and significant advancements in R&D. However, challenges such as increased carbon emissions, supply chain investments, and financial losses were noted.Read More>---
NVO Stock 12 Month Forecast
Average Price Target
$84.83
▲(34.91% Upside)
Technical Analysis
Best Analysts Covering NVO
1 Year
1 Year Success Rate
8/24 ratings generated profit
1 Year Average Return
-4.20%
reiterated a buy rating 20 days ago
Copying Sachin Jain's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -4.20% per trade.
---